Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-cash Items: 2010-2024

Historic Non-cash Items for Ironwood Pharmaceuticals (IRWD) over the last 1 years, with Dec 2024 value amounting to $4.5 million.

  • Ironwood Pharmaceuticals' Non-cash Items rose 55.49% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year increase of 55.49%. This contributed to the annual value of $4.5 million for FY2024, which is 55.49% up from last year.
  • According to the latest figures from Q4 2024, Ironwood Pharmaceuticals' Non-cash Items is $4.5 million, which was up 55.49% from $2.9 million recorded in Q4 2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Non-cash Items ranged from a high of $5.8 million in Q4 2022 and a low of $2.9 million during Q4 2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Non-cash Items value was $4.5 million (recorded in 2024), while the average stood at $4.4 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first slumped by 77.75% in 2020, then skyrocketed by 55.49% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-cash Items (Quarterly) stood at $5.6 million in 2020, then declined by 19.33% to $4.5 million in 2021, then rose by 27.78% to $5.8 million in 2022, then crashed by 49.53% to $2.9 million in 2023, then spiked by 55.49% to $4.5 million in 2024.
  • Its Non-cash Items stands at $4.5 million for Q4 2024, versus $2.9 million for Q4 2023 and $5.8 million for Q4 2022.